Neshima Medical develops Liquid Foam Therapy (LiFT™) technology for targeted delivery of therapeutics directly to the lungs. This platform achieves concentrations up to 100-fold higher than standard-of-care, effectively treating localized respiratory infections like pneumonia. The unique fluid properties of LiFT™ also enable penetration through mucus obstructions to reach difficult infection sites.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods of delivering respiratory drugs, such as intravenous administration and aerosol therapies, often result in limited drug concentrations in the lungs, particularly in the presence of mucus obstructions or constricted airways. This can lead to prolonged hospitalizations and increased mortality rates, especially in ventilated pneumonia patients.
Solution
Neshima Medical is developing LiFT RapidHeal™, a liquid-foam therapy designed for targeted respiratory drug delivery. This technology enables topical administration of high doses of therapeutics, including antibiotics, directly into the lungs, even through constricted and mucus-obstructed airways. The unique fluid properties of the foam allow it to reach infected regions beyond obstructions, delivering concentrations known to combat resistant bacteria. By delivering higher concentrations of drugs directly to the site of infection, LiFT aims to improve treatment efficacy, reduce hospitalization times, and decrease mortality rates associated with respiratory infections. Neshima plans to expand the application of LiFT to address various types of pneumonia, airway washes, and fast-acting bronchodilator rescue therapy for severe asthma, with a long-term vision of delivering stem cells to regenerate lungs in COPD patients.
Target Audience
The primary target audience includes medical professionals treating ventilated pneumonia patients, as well as those managing other respiratory conditions such as asthma, COPD, and cystic fibrosis.
Features
- Liquid-foam formulation for enhanced drug delivery to the lungs
- Ability to bypass mucus obstructions and airway narrowings
- Potential for 100-fold higher drug concentrations in the lungs compared to standard-of-care
- Topical administration for targeted delivery and reduced systemic exposure
- Suitable for delivering a range of therapeutics, including antibiotics, cells, and large particles
- Applicability to various respiratory conditions, including pneumonia, asthma, COPD, IPF, and CF